HC Wainwright & Co. analyst Mitchell Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and maintains $7 price target.
- Headlines
- HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Unlock the Full List
Latest
12:35
The stock price of PAYTM in India has dropped by 5.6%, making it one of the stocks with the largest decline in the NIFTY Middle Cap Index components.
12:29
JEFFERIES: Raised ConocoPhillips' target price from $146 to $148.
COP+0.23%
12:19
The Chinese representative expressed hope that the situation in the Middle East can move in the right direction with the ceasefire in Gaza.